The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacoepidemiology
Volume 15 - 2024 |
doi: 10.3389/fphar.2024.1399172
Suspected Adverse Drug Reactions of Rivaroxaban Reported in the United States Food and Drug Administration Adverse Event Reporting System Database: A Pharmacovigilance Study
Provisionally accepted- 1 Southeast University, Nanjing, China
- 2 Shenzhen Institute of Pharmacovigilance and Risk Management, Shenzhen, China
Purpose This study aimed to characterize the safety profiles of rivaroxaban-associated suspected adverse events by mining the Food and Drug Administration Adverse Event Reporting System (FAERS). Methods A disproportionality analysis of spontaneously reported suspected adverse drug reactions (ADRs) was conducted. The reports in FAERS from 2014 to 2024 were compiled. Frequentist and Bayesian statistics were both applied to calculate drug-AE combinations in system organ classes and preferred-term levels. Reporting odds ratio (ROR), proportional reporting ratio (PRR), the Medicines and Healthcare products Regulatory Agency (MHRA), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) methods were analyzed and used to compare the suspected AEs. Results Of 77,384 ADR reports, 66705 (86.20%) were serious rivaroxaban AE reports. The most common age group was above 65 years. The suspected adverse effects of rivaroxaban emerging for SOC primarily included “Gastrointestinal disorders”; “Injury, poisoning, and procedural complications”, “Nervous system disorders” and “Vascular disorders”. Ranked by EBGM, the top signal strength of suspected AE signals of rivaroxaban under ROR algorithm at the PT level were “Haemorrhagic arteriovenous malformation” (N = 571, ROR = 756.520, PRR = 754.029, IC = 7.197, EBGM)= 146.725), and “Gastrointestinal vascular malformation haemorrhagic” (N =197, ROR = 211.138, PRR = 210.950, IC = 6.614, EBGM = 97.923). Moreover, uncommon but significantly suspected AE signals, such as “Coagulation factor X level increased”, “Basal ganglia haematoma”, and “Proctitis haemorrhagic” were observed. Notably, “Gastrointestinal haemorrhage” , “Upper gastrointestinal haemorrhage” and “Internal haemorrhage” exhibited relatively high occurrence rates and signal strengths. From 2014 to 2024, the IC values of rivaroxaban-associated suspected AEs for “Surgical and medical procedures” and “Cardiac disorders” showed an annual increasing trend in the time-span analysis. The exciting finding was that the MGPS algorithm revealed a higher risk of suspected AEs under the “Investigations” category. Moreover, the results of signal mining for the three main types of indication populations with adverse drug reactions (ADRs), including Atrial fibrillation, Cerebrovascular accident prophylaxis, and Deep vein thrombosis were shown that “Gastrointestinal haemorrhage”, “Epistaxis”, “Haematuria”, “Rectal haemorrhage”, and “Upper gastrointestinal haemorrhage” were detected as the most common and significant signals of suspected adverse events.
Keywords: Suspected adverse event, Disproportionality analysis, drug safety, Pharmacovigilance, rivaroxaban
Received: 11 Mar 2024; Accepted: 26 Aug 2024.
Copyright: © 2024 Wu, Wu, Tang, Wang, Fenfang, Zhang, Li, Li, Wang, Wu and Hong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiang Hong, Southeast University, Nanjing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.